# Reproducibility of published model-based cancer drug cost-effectiveness analyses: a study protocol for a cross-sectional analysis

**Authors:** Mikael Svensson, Jonathan Siverskog, Naimi Johansson, Martin Henriksson

PMC · DOI: 10.1136/bmjopen-2024-096719 · BMJ Open · 2025-06-20

## TL;DR

This study will assess how reproducible cancer drug cost-effectiveness analyses are by evaluating the transparency of published research.

## Contribution

The study introduces a protocol to evaluate the reproducibility of model-based cancer drug cost-effectiveness analyses.

## Key findings

- The study will identify up to 150 CEA studies for reproducibility assessment.
- Results will be published in peer-reviewed journals and conferences.
- Collected data will be made publicly available in an online repository.

## Abstract

Model-based cost-effectiveness analysis (CEA) of pharmaceuticals informs reimbursement and pricing in many healthcare systems, and it is essential that CEA evidence is valid and reliable. Several studies have reported lacking transparency in CEA studies. In this study protocol, we describe a study that will investigate whether model-based CEA studies of cancer drugs are transparent and informative enough to enable the reproduction of study findings.

This study protocol outlines a study where we will identify CEA studies indexed in MEDLINE from 2015 to 2023 based on predefined search terms. We will include English-language CEA studies evaluating pharmaceutical treatments based on decision-analytical modelling methods that report cost-effectiveness results using life-years, quality-adjusted life-years and/or disability-adjusted life-years as health outcome metric(s). Two authors will screen abstracts and full text for inclusion. We anticipate that a maximum of 150 studies will be included after a full-text review. A data extraction template is designed to capture information used to determine reproducibility together with other information that will be analysed as potential determinants of reproducibility in logistic and linear regression analyses.

This study design has been deemed exempt from ethical approval. All collected data will be made available in an online repository that will host the study protocol and other supplementary data. Results from this proposed study will be published in peer-reviewed journals and at scientific conferences and workshops.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** cancer (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12182205/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12182205/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12182205/full.md

---
Source: https://tomesphere.com/paper/PMC12182205